Advertisement

Tumor Markers for Monitoring Therapy in Lung Cancer

  • C. Gropp
  • K. Havemann
  • R. Holle
Conference paper

Abstract

The ectopic production of several peptide hormones in patients with lung cancer has been described by several authors in recent years. Hormones which are frequently elevated in sera of patients with small cell lung cancer (SCLC) at diagnosis are summarized in Table 1. Only results based on sufficiently large numbers of patients are included. The incidence of elevated levels of a given peptide hormone varies depending on the assay system, the antibodies used, and the upper limits employed in the different studies. For many of the hormones listed in Table 1, increased levels can be detected at diagnosis in up to 70% of patients, and in many cases several hormones are elevated in parallel. Often, however, blood levels are only marginally increased, and evidence of excessive production may be present in only up to 25% [2].

Keywords

Tumor Marker Small Cell Lung Cancer Small Cell Carcinoma Peptide Hormone Marker Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carney DN, Marangos PJ, Ihde DC (1982) Serum neuron-specific enolase: a marker of disease extent and response to therapy in patients with small cell lung cancer. Lancet 1:583–585PubMedCrossRefGoogle Scholar
  2. 2.
    Carney DN, Broder L, Edelstein M, Gazdar AF, Hansen M, Havemann K, Matthews MJ, Sorenson GD, Vindelov L (1983) Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 67:27–35PubMedGoogle Scholar
  3. 3.
    Gropp C, Luster W, Havemann K, Lehmann FG (1981) ACTH, calcitonin, a-MSH, β-en- dorphin, parathormone and β-HCG in sera of patients with lung cancer. In: Uhlenbruck G, Wintzer G (eds) CEA und andere Tumormarker. Tumor Diagnostik, Leonberg, pp 358–363Google Scholar
  4. 4.
    Hansen M, Hammer M, Hummer L (1980) ACTH, ADH, and calcitonin concentrations as marker of response and relapse in small cell carcinoma of the lung. Cancer 46:2062–2067PubMedCrossRefGoogle Scholar
  5. 5.
    Krauss S, Macy S, Ichiki AT (1981) A study of immunoreactive calcitonin, ACTH and CEA in lung cancer and other malignancies. Cancer 47:2485–2492PubMedCrossRefGoogle Scholar
  6. 6.
    Luster W, Gropp C, Sostmann H, Kalbfleisch H, Havemann K (1982) Demonstration of immunoreactive calcitonin in sera and tissues of lung cancer patients. Eur J Cancer Clin Oncol 18:1275–1283PubMedCrossRefGoogle Scholar
  7. 7.
    North WG, Maurer H, Valtin H, O’Donell JF (1980) Human neurophysins as potential tumor markers for small cell carcinoma of the lung: Application of specific radioimmunoassays. J Clin Endocrinol Metab 51:892–897PubMedCrossRefGoogle Scholar
  8. 8.
    Odell WD, Wolfsen AR, Bachelot I, Hirose FM (1979) Ectopic production of lipotropin by cancer. Am J Med 66:631–638PubMedCrossRefGoogle Scholar
  9. 9.
    Ratcliffe JG, Podmore J, Stack BHR, Spilg WGS, Gropp C (1982) Circulating ACTH and related peptides in lung cancer. Br J Cancer 45:230–238PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • C. Gropp
    • 1
  • K. Havemann
  • R. Holle
  1. 1.Zentrum für Innere MedizinKlinikum der Philipps-UniversitätMarburgGermany

Personalised recommendations